Scientific intelligence record

Experience 2.0

Long-acting GHRH analog

CJC-1295

Also known as: CJC1295, CJC-1295 DAC, Drug Affinity Complex GRF

CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.

Record status

Traceability partial

Last meaningful update: 9/8/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/8/2026
Last human review:: 9/8/2026

Governed reviewed evidence

Governed records, not an efficacy score or total literature count.

Evidence boundary

0 / 25

Claim-linked support versus recorded evidence.

Research gaps

Unresolved questions remain visible.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Governed reviewed evidence

Reviewed database records promoted through the governed publication workflow.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

No public institutional claim is represented yet

This does not mean the scientific literature contains no findings. It means no reviewed institutional claim has been represented here.

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

The chemistry record exists, but no displayable molecular fields have been entered yet.

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2006 · study · Temporal status not established
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
peer_reviewed_research
2006 · study · Temporal status not established
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
peer_reviewed_research
2006 · study · Temporal status not established
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
peer_reviewed_research
2009 · study · Temporal status not established
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
peer_reviewed_research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

peer_reviewed_research

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Claim → Evidence

Incomplete

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Incomplete links: claim-to-evidence

Inspect 25 source paths ↓

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Reviewed jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union (EMA)

Regulator: EMA

not_approved

As of: 9/8/2026 · Temporal status not established

European Medicines Agency medicines database

United States (FDA)

Regulator: FDA

not_approved

As of: 9/8/2026 · Temporal status not established

Drugs@FDA: FDA-Approved Drugs

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.

Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.

Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.

Contradictory and qualifying evidence must remain visible rather than being silently discarded.

Absence of represented evidence is not evidence that research does not exist.

Research gaps identify unresolved questions; they are not negative conclusions.

Regulatory status is distinct from scientific evidence quality.

Media relationships provide context and explanation; they do not increase the strength of scientific evidence.

A section with no represented records is an incomplete project record, not a scientific conclusion.

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula: C165H269N47O46
Molecular weight: 3647.2 g/mol
Exact identity / sequence notation: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Nε-3-maleimidopropionyl)-NH2
Identity-defining modifications: D-Ala2
Gln8, Ala15, and Leu27 substitutions
Lys30 Nε-3-maleimidopropionyl DAC
C-terminal amide
PubChem CID: 91971820
InChIKey: ZUQGTWKGESAQCD-ZGFIGYLBSA-N

DAC-bearing molecule; it is not the distinct 29-residue no-DAC analog catalogued as PubChem CID 56841945.

Sources: NIH PubChem — CJC-1295, DAC-bearing · reviewed 2026-09-17

Representative sequence-derived model

CJC-1295

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

No public institutional claim is represented yet

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Follow the scientific relationships

peer_reviewed_research

Follow the record back to its source

What contributors reported

Reviewed jurisdictional records

not_approved

not_approved

Media connected to this scientific record

Read the scientific record with its boundaries intact

Practice-defining evidence

Strong supporting evidence

Contextual evidence

Signal-generating evidence

Tier and confidence answer different questions

Structural visualization and provenance

Evidence Passport

Evidence integrity map

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

The study of doping market: How to produce intelligence from Internet forums.

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

The study of doping market: How to produce intelligence from Internet forums.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Regulatory review: not_approved

Regulatory review: not_approved